康华生物(300841) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 266,736,074.86, representing a 12.48% increase compared to CNY 237,149,805.31 in the same period last year[6] - Net profit attributable to shareholders for Q1 2022 was CNY 135,277,246.77, a 34.60% increase from CNY 100,499,516.16 in the previous year[6] - Basic earnings per share for Q1 2022 were CNY 1.5087, down 35.10% from CNY 1.6750 in the previous year[6] - The company reported a net profit margin improvement, with net profit increasing due to higher revenue and controlled costs[39] - The net profit for the current period is 135,277,246.77, compared to 100,499,516.16 in the previous period, representing an increase of approximately 34.6%[42] - The total profit for the current period is 156,134,338.16, up from 118,963,858.22 in the previous period, indicating a growth of about 31.2%[42] Cash Flow - The net cash flow from operating activities was negative CNY 111,805,582.88, a decline of 76.02% compared to negative CNY 63,517,522.38 in the same period last year[6] - Cash flow from operating activities generated a net outflow of -111,805,582.88, compared to -63,517,522.38 in the previous period, reflecting a worsening cash flow situation[47] - Total cash inflow from operating activities increased by 40.98% to 174,143,515.60 CNY, attributed to higher sales collections[15] - Total cash outflow from operating activities rose by 52.88% to 285,949,098.48 CNY, driven by increased material reserves and payments[15] - The net cash flow from investing activities decreased by 57.70% to -171,578,869.93 CNY, due to increased payments for projects and equipment[15] - The cash flow from investing activities resulted in a net outflow of -171,578,869.93, compared to -108,803,254.71 in the previous period, indicating increased investment expenditures[52] - The net cash flow from financing activities was 34,874,462.61 CNY, reflecting an increase in bank loans and stock repurchases[18] - The company raised 40,000,000.00 in cash from financing activities, with a net cash inflow of 34,874,462.61 from financing activities overall[52] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 3,102,413,394.89, an increase of 2.80% from CNY 3,018,041,385.96 at the end of the previous year[6] - Current assets totaled CNY 1,981,125,743.65, up from CNY 1,942,586,927.29, indicating an increase of 1.99%[30] - The total liabilities decreased to CNY 298,164,404.81 from CNY 347,740,657.31, a reduction of 14.2%[36] - Shareholders' equity attributable to the parent company was CNY 2,804,248,990.08, up 5.02% from CNY 2,670,300,728.65 at the end of the previous year[6] - Shareholders' equity rose to CNY 2,804,248,990.08, compared to CNY 2,670,300,728.65, indicating an increase of 5.0%[39] Inventory and Accounts Payable - Inventory increased by 36.47% to CNY 143,963,001.95, attributed to an increase in finished goods and material stock[14] - The company reported a significant increase in accounts payable by 227.21% to CNY 19,823,539.43, due to increased purchases of raw materials[14] Research and Development - Research and development expenses rose to CNY 21,011,414.14, up from CNY 16,753,131.31, marking a significant increase of 25.5%[39] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,720[19] - The largest shareholder, Aokang Group Co., Ltd., holds 16.08% of shares, with 14,470,312 shares pledged[19]